Osteoporose – Therapie nach Fragilitätsfrakturen

Zusammenfassung

Eine rasche chirurgische Versorgung der Frakturen und folglich eine möglichst rasche nachfolgende Mobilisierung sind mittlerweile zum Standard der Frakturversorgung im Alter geworden. Die Therapie der zugrunde liegenden Osteoporose tritt häufig in den Hintergrund der medizinischen Akutversorgung. Nur ein kleiner Anteil der Patienten ist vortherapiert, nur wenigen Patienten wird nach erlittener osteoporotischer Fraktur eine umfassende osteologische Medikation verschrieben, die die Progredienz der Osteoporose mindern und das Eintreten weiterer Frakturen reduzieren soll. Diese Minderversorgung ist in der Literatur als „osteoporosis care gap” bekannt. Der folgende Beitrag gibt einen Überblick über die Therapiemöglichkeiten und beantwortet zahlreiche Fragestellungen aus dem klinischen Alltag.

Summary

Immediate fracture stabilisation and fast remobilisation have become standard procedures after a fragility fracture due to osteoporosis. Treatment of an underlying osteoporosis has often taken a back seat in clinical practice. Only a small group of patients are already under osteoporosis medication and even after a fracture only few patients receive an osteoporosis drug therapy with the aim to postpone osteoporosis and to reduce the rate of further fractures. In literature this has been described as “osteoporosis care gap”. The following article presents an overview over treatment options, and answers different questions from a clinical perspective.

Schlüsselwörter

Osteoporose - Frakturen - Therapieeinleitung - klinisches Management

Keywords

Osteoporosis - fractures - start of therapy - clinical management

• Literatur

• 1 Liu H, Paige NM, Goldzweig CL. et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med 2008; 148: 685-701.
• 2 Pietschmann P, Azizi-Semrad U, Pils K. et al. Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior´s residences. Wien Klin Wochenschr 2010 August 23. [Epub ahead of print]. doi 10.1007/s00508–010–1428–8.
• 3 Wright RM. Use of osteoporosis medications in older nursing facility residents. J Am Med Dir Assoc 2007; 08: 453-457.
• 4 Haaland DA, Cohen DR, Kennedy CC. et al. Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatr 2009; 09: 28 doi 10.1186/1471–2318–9–28..
• 5 Metge CJ, Leslie WD, Manness LJ. et al. Maximizing Osteoporosis Management in Manitoba Steering Committee. Postfracture care for older women: gaps between optimal care and actual care. Can Fam Physician 2008; 54: 1270-1276.
• 6 Giangregorio LM, Jantzi M, Papaioannou A. et al. Osteoporosis management among residents living in long-term care. Osteoporos Int 2009; 20: 1471-1478.
• 7 Jennings LA, Auerbach AD, Maselli J. et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 2010; 58: 650-657.
• 8 WHO. Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva; 1998: 59.
• 9 Bogoch ER, Elliot-Gibson V, Beaton DE. et al. Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am 2006; 88: 25-34.
• 10 http://www.shef.ac.uk/FRAX accessed 11 May 2013.
• 11 Kanis JA, McCloske V, Johannsson H. et al., on behalf of the scientific advisory board of the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) and the committee of scientific advisors of the international osteoporosis foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 2013; 24: 23-57.
• 12 Curtis JR, Arora T, Matthews RS. et al. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc 2010; 11: 584-591.
• 13 Bolland MJ, Avenell A, Baron JA. et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341: c3691.
• 14 Bischoff-Ferrari HA, Willett WC, Orav EJ. et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367: 40-49 Erratum in: N Engl J Med 2012; 367: 481.
• 15 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
• 16 Goldhahn J, Féron JM, Kanis J. et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 2012; 90: 343-353.
• 17 Eriksen EF, Lyles KW, Colón-Emeric CS. et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 2009; 24: 1308-1313.
• 18 Gosch M, Kammerlander C, Roth T. et al. Surgeons save bones: an algorithm for orthopedic surgeons managing secondary fracture prevention. Arch Orthop Trauma Surg. 2013 May 17. [Epub ahead of print]. PubMed PMID: 23681470.
• 19 Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17: 1645-1652.
• 20 Lyles KW, Colón-Emeric CS, Magaziner JS. et al., for the HORIZON Recurrent Fracture Trial. Zole- dronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med 2007; 357: 1799-1809.
• 21 Cummings SR, San JMartin, McClung MR. et al. Denosumab for prevention of fractures in postmenopaual women with osteoporosis. N Engl J Med 2009; 361: 756-765.
• 22 Gosch M, Kammerlander C, Pils K. et al. Osteoporotic treatment options in geriatric patients. Z Gerontol Geriatr 2012; 45: 417-428.
• 23 Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 2011; 93: 1583-1587.
• 24 http://www.mhra.gov.uk/home/groups/plp/docu ments/drugsafetymessage/con282759.pdf accessed 14.10.2013.
• 25 Ettinger D, Black DM, Mitlak BH. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645.
• 26 http://www.nice.org.uk/nicemedia/ live/11748/42447/42447.pdf accessed 04 January 2013.
• 27 Diez-Perez A, Adachi JD, Agnusdei D. et al. IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis. Osteoporos Int 2012; 23: 2769-2774.